UGT2B7型
体内
葡萄糖醛酸化
药理学
酶
药物代谢
体外
药品
葡萄糖醛酸转移酶
医学
化学
生物化学
微粒体
生物
生物技术
作者
Yun Xu,Mingchun Liu,Xinyuan Zhang,Jun Wang,Dongmin Gu,Yang Wang
摘要
Background: Inhibition of drug-metabolizing enzymes (DMEs) has been regarded as one of the most important reason for clinical drug-drug interaction.Aim: The aim of the present study is to evaluate the inhibition of bakuchiol towards UDP-glucuronosyltransferase (UGT) 2B isoforms.Methods: In vitro recombinant UGT2B-catalyzed 4-methylumbelliferone glucuronidation was used as the probe reaction.Dixon plot and Lineweaver-Burk plot were employed to determine the inhibition kinetic type, and nonlinear regression of data was utilized to calculate the inhibition kinetic parameter (K i ).In vitro-in vivo extrapolation (IVIVE) was carried out to predict in vivo inhibition magnitude.Results: Among the tested UGT2B isoforms, UGT2B7 was inhibited by the strongest intensity.The noncompetitive inhibition was demonstrated by the results obtained from Dixon plot and Lineweaver-Burk plot.The K i value was calculated to be 10.7 μM.In combination with the reported concentration after an intravenous administration of bakuchiol (15 mg/kg) in rats, the high risk of in vivo inhibition of bakuchiol towards UGT2B7-catalyzed metabolism of drugs was indicated.Conclusion: All these results provide an important information for the risk evaluation of the clinical utilization of bakuchiol.
科研通智能强力驱动
Strongly Powered by AbleSci AI